European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma’s Treatment for Sanfilippo Syndrome (Type A)

Posted on by

YONGIN, South Korea, Jan. 22, 2024 /PRNewswire/ — GC Biopharma Corp. (006280.KS) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its intracerebroventricular (ICV) Enzyme Replacement Therapy (ERT) candidate, GC1130A, designed for Sanfilippo…